Cosmos Health Inc. Common Stock (COSM)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and sell at a discount to intrinsic value. Cosmos Health does not fit that mold. It distributes and sells nutraceuticals and other healthcare products across several countries, but in fiscal 2025, the year ended 2025-12-31, it reported revenue of $65.3M and a net loss of $19.1M. In fiscal 2024, the year ended 2024-12-31, revenue was $54.4M and net loss was $16.2M; in fiscal 2023, revenue was $53.4M and net loss was $18.5M. Growth in sales is real, but it has not produced profits. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $19.0M and net income was -$6.1M, worse than the -$2.8M loss in fiscal Q2 2025, the quarter ended 2025-06-30. That suggests the business needs more scale or better cost control, not just more revenue. The FairStock metrics as of the $0.38 close on 2026-10-13 show a negative P/E of -0.57 and P/B of 1.47, so I am not paying below book for a loss-making operation. Return on equity is -104%, return on capital employed is -18.42%, and trailing free cash flow is -$10.0M, a -25.8% FCF yield—cash is going out. The debt-to-equity ratio is 0.77, and the Altman Z-score of -2.48 suggests financial stress. The Piotroski F-score is 4/9, middling at best. FairStock's Lynch category is none because the company lost money in each of the last four years. With a beta of 4.17 and a 52-week range of $0.16 to $1.24, the stock is highly speculative. Until Cosmos can show sustained positive earnings and free cash flow, it looks like a cigar butt without a clear light.

In plain English: Cosmos Health sells medicines, supplements, devices, and cosmetics in several countries. Sales are growing, but the company has lost money for years and is burning cash, so the business looks weak. At 38 cents a share, the price does not look clearly cheap because there are no profits or positive cash flow to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer